The Lung Cancer Drugs Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2011-2022) and extends its insights into a ten-year forecast period (2024-2033).
Learn More On The Lung Cancer Drugs Market:
https://www.thebusinessresearchcompany.com/report/lung-cancer-drugs-global-market-report
According to The Business Research Company’s Lung Cancer Drugs Global Market Report 2024, The lung cancer drugs market size has grown rapidly in recent years. It will grow from $42.3 billion in 2023 to $47.72 billion in 2024 at a compound annual growth rate (CAGR) of 12.8%. The growth in the historic period can be attributed to epidemiology and demographics, regulatory approvals, healthcare infrastructure, patient awareness and education.
The lung cancer drugs market size is expected to see rapid growth in the next few years. It will grow to $74.81 billion in 2028 at a compound annual growth rate (CAGR) of 11.9%. The growth in the forecast period can be attributed to health insurance and reimbursement policies, healthcare infrastructure and access, emerging markets. Major trends in the forecast period include advancements in targeted therapies, immunotherapy, genomic profiling, clinical trials and research, .
The rising prevalence rate of lung cancer is a major driver for the lung cancer drugs market. This is mainly because an increase in the prevalence and incidence rate of lung cancer cases propels the need for drugs that enable efficient and fast treatment of the disease. It also drives the industry to maintain a strong pipeline of drugs. For instance, in January 2023, according to the American Cancer Society, a US-based voluntary health organization dedicated to eliminating cancer, about 238,340 new cases of lung cancer (117,550 in men and 120,790 in women) and about 127,070 deaths from lung cancer (67,160 in men and 59,910 in women) were estimated in 2023. Therefore, the rising prevalence rate of lung cancer is driving the growth of the lung cancer drugs market.
Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample_request?id=2567&type=smp
The lung cancer drugs market covered in this report is segmented –
1) By Drugs: Gemzar; Paraplatin; Taxotere; Navelbine; Avastin; Tarceva; Iressa; Other Drugs
2) By Disease Type: Small cell lung cancer (SCLC); Non-small cell lung cancer (NSCLC)
3) By End User: Hospitals; Clinics; Other End-Users
The lung cancer drugs market report table of contents includes:
- Executive Summary
- Lung Cancer Drugs Market Characteristics
- Lung Cancer Drugs Market Trends And Strategies
- Lung Cancer Drugs Market – Macro Economic Scenario
- Global Lung Cancer Drugs Market Size and Growth
.
.
.
- Global Lung Cancer Drugs Market Competitive Benchmarking
- Global Lung Cancer Drugs Market Competitive Dashboard
- Key Mergers And Acquisitions In The Lung Cancer Drugs Market
- Lung Cancer Drugs Market Future Outlook and Potential Analysis
- Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
